Thomas Sepe

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Péter Ferenci, David Bernstein, Jacob Lalezari et al. · New England Journal of Medicine · 2014 · 690 citations · Full text

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

Naga Chalasani, Manal F. Abdelmalek, Guadalupe García–Tsao et al. · Gastroenterology · 2019 · 326 citations · Full text

Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects

John R. Saltzman, Kris V. Kowdley, Marcos Pedrosa et al. · Gastroenterology · 1994 · 173 citations

Aging, Medicine, Microbiology +3